• Home Blog Tag Chronic spontaneous urticaria market

chronic spontaneous urticaria market

Apr 22, 2025

FDA Approves Sanofi/Regeneron’s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead’s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest’s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure’s AMT-130 Granted FDA Breakthrough for Huntington’s; NeuroNOS’ BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome

Mar 11, 2025

Neurotech’s ENCELTO Becomes First FDA-Approved Treatment for MacTel Type 2; Plus Therapeutics’ Rhenium Obisbemeda Gets FDA Orphan Status; Novo Nordisk Cuts WEGOVY to $499/Month; Capricor’s Deramiocel Wins FDA Priority Review; Celltrion’s OMLYCLO Becomes First Interchangeable XOLAIR Biosimilar

Mar 06, 2024

Major Highlights and Insights from the AAAAI Annual Meeting, 2024

Aug 14, 2023

Towards a Promising Future: Unveiling Advancements in Chronic Spontaneous Urticaria (CSU) Treatment

Newsletter/Whitepaper